Efficacy and Safety Study of MP-513 in Patients With Type 2 Diabetes

• Status: Completed
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the efficacy and safety and to determine the appropriate dose for phase 3 confirmatory trial, of MP-513 (Teneligliptin) in patients with type 2 Diabetes based on the change of HbA1c and adverse events after 12 weeks administration once daily in multi-center, randomized, double-blind, placebo-controlled, parallel assignment manner.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Mitsubishi Tanabe Pharma Corporation

Criteria

Inclusion Criteria:

• Patients who are 20 - 75 years old

• Patients who are under dietary management and taking therapeutic exercise for diabetes over 12 weeks before administration of investigational drug

• Patients whose HbA1c is 6.5 - 9.5%

• Patients who were not administered drugs prohibited for concomitant use within 12 weeks before administration of investigational drug.

Exclusion Criteria:

• Patients with type 1 diabetes, diabetes mellitus caused by pancreas failure, or secondary diabetes (Cushing disease, acromegaly, etc)

• Patients with Class III/IV heart failure symptoms according to New York Heart Association (NYHA) functional classification

• Patients with serious diabetic complications

• Patients who are habitual excessive alcohol consumption.

• Patients with severe hepatic disorder or severe renal disorder.

• Pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception